| Q46698824 | Acute kidney injury during vancomycin therapy in critically ill children |
| Q41103109 | Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure |
| Q40716347 | Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection? |
| Q38071675 | Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis |
| Q92664326 | Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial |
| Q93074049 | Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA) |
| Q38409273 | Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. |
| Q90198604 | Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population |
| Q44770615 | Development of acute kidney injury during continuous infusion of vancomycin in septic patients. |
| Q35141184 | Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies |
| Q45951342 | Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. |
| Q57216392 | Evaluation of risk factors for vancomycin-induced nephrotoxicity |
| Q38245931 | Factors associated with acute kidney injury in children receiving vancomycin |
| Q64239043 | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
| Q35123536 | High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q39127162 | Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. |
| Q38623078 | In Vitro Activity of Gentamicin-Loaded Bioabsorbable Beads against Different Microorganisms |
| Q33939018 | Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children |
| Q59135453 | Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics |
| Q40478665 | Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. |
| Q30569251 | Prevention of vancomycin induced nephrotoxicity: a review of preclinical data |
| Q46700963 | Reply to Tarchini |
| Q40483780 | Retrospective analysis of vancomycin treatment outcomes in Chinese paediatric patients with suspected Gram-positive infection |
| Q33892706 | Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury: a prospective, clinical, non-interventional, observational study |
| Q38061039 | Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter |
| Q36148828 | The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis |
| Q34494676 | Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients |
| Q35959558 | Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin |
| Q36381339 | Usefulness of a decision tree model for the analysis of adverse drug reactions: Evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure |
| Q45394930 | Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? |
| Q42524512 | Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia |
| Q34433066 | Vancomycin revisited - 60 years later |
| Q37992997 | Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review |